SCINAI IMMUNOTHERAPEUTICS LT (SCNI) Stock News

USA - NASDAQ:SCNI - US09073Q3039 - ADR

1 USD

-0.09 (-8.68%)

Last: 11/13/2025, 8:00:02 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

SCNI Latest News, Press Relases and Analysis

All

Press Releases

a month ago - By: Scinai Immunotherapeutics Ltd.

Scinai Awarded Israel Innovation Authority Grant to Expand Fill-and-Finish CDMO Capabilities

2 months ago - By: Scinai Immunotherapeutics Ltd.

Scinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance Sheet

3 months ago - By: Benzinga - Mentions: NBY AEMD EVOK THAR ...

12 Health Care Stocks Moving In Thursday's Pre-Market Session

3 months ago - By: Benzinga - Mentions: AEMD MLSS WINT THAR ...

12 Health Care Stocks Moving In Wednesday's After-Market Session

a year ago - By: InvestorPlace

SCNI Stock Earnings: Scinai Immunotherapeutics Reported Results for Q2 2024

a year ago - By: BusinessInsider

News Image

SCNI Stock Earnings: Scinai Immunotherapeutics Reported Results for Q2 2024

4 months ago - By: Scinai Immunotherapeutics Ltd.

Scinai Announces New Peer-Reviewed Publication Supporting PC111 as a Disease-Modifying Therapy for Pemphigus and SJS/TEN

5 months ago - By: Scinai Immunotherapeutics Ltd.

Scinai Highlights Award-Winning Science Behind PC111 as Key Pincell Researcher Receives "Oscar of Italian Dermatology"

5 months ago - By: Scinai Immunotherapeutics Ltd.

Scinai Immunotherapeutics Receives Italian Government Clearance Under Golden Power Regulation for Potential Acquisition of Pincell S.r.l.

6 months ago - By: Scinai Immunotherapeutics Ltd.

Scinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash Burn

6 months ago - By: Scinai Immunotherapeutics Ltd.

Scinai Announces Annual Financial Results for 2024

8 months ago - By: Scinai Immunotherapeutics Ltd.

Scinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions

8 months ago - By: Scinai Immunotherapeutics Ltd.

Scinai to Connect with Investors, Showcase its Innovative I&I pipeline and its Boutique cGMP Biologics CDMO during BIO-Europe Spring 2025

8 months ago - By: Scinai Immunotherapeutics Ltd.

SCINAI IMMUNOTHERAPEUTICS ANNOUNCES $10 MILLION STANDBY EQUITY PURCHASE AGREEMENT

10 months ago - By: Scinai Immunotherapeutics Ltd.

Scinai to Connect with Investors and Pharma Leaders at Upcoming Key US Conferences

a year ago - By: Scinai Immunotherapeutics Ltd.

Scinai Immunotherapeutics Establishes U.S. Subsidiary for CDMO Business Unit, Scinai Bioservices Inc.

a year ago - By: Scinai Immunotherapeutics Ltd.

Prof. Michael Schön, Director of Dermatology and Venereology at the University Medical Center Göttingen, Germany (UMG), Joins Scinai Immunotherapeutics' Scientific Advisory Board

a year ago - By: Scinai Immunotherapeutics Ltd.

Dr. Jonathan Sadeh, Former Senior Vice President of Immunology R&D at Bristol-Myers Squibb, Joins Scinai Immunotherapeutics' Scientific Advisory Board

a year ago - By: Scinai Immunotherapeutics Ltd.

Scinai Publishes Financial Results and Provides Business Update; Shareholders' Equity up from negative $7.3 million as of June 30, 2024, to positive $10 million

a year ago - By: Invezz

BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) CEO Featured Guest on Latest Episode of BioMedWire Podcast

a year ago - By: Scinai Immunotherapeutics Ltd.

Scinai Regains Full Compliance with Nasdaq Listing Requirements

a year ago - By: Scinai Immunotherapeutics Ltd.

Scinai Announces Closing of Loan Restructuring Agreement with European Investment Bank Converting Approximately $29 million of Debt to Preferred Equity and Leaving Debt Balance of $273,000

a year ago - By: Invezz

BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Enters Into $2M Investment Commitment Agreement with Its Largest Existing Shareholder

a year ago - By: Scinai Immunotherapeutics Ltd.

Scinai Announces Entering into $2 Million Private Equity Commitment Agreement with its largest Existing Shareholder